ADMA Biologics Inc (ADMA)vsAlnylam Pharmaceuticals Inc (ALNY)
ADMA
ADMA Biologics Inc
$8.75
+0.34%
HEALTHCARE · Cap: $2.02B
ALNY
Alnylam Pharmaceuticals Inc
$291.37
-0.19%
HEALTHCARE · Cap: $39.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 741% more annual revenue ($4.29B vs $509.86M). ADMA leads profitability with a 32.4% profit margin vs 12.6%. ADMA trades at a lower P/E of 12.8x. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ADMA
Hold49
out of 100
Grade: D+
ALNY
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADMA.
Margin of Safety
+86.4%
Fair Value
$2363.38
Current Price
$291.37
$2072.01 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Keeps 32 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
15.9% revenue growth
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Areas to Watch
Earnings declined 52.8%
Operating margin of -123.4%
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Profit Margin, Altman Z-Score. Profitability is solid with margins at 32.4% and operating margin at -123.4%. Revenue growth of 15.9% demonstrates continued momentum.
Bull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : ADMA
The primary concerns for ADMA are EPS Growth, Operating Margin.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 74.1x leaves little room for execution misses.
Key Dynamics to Monitor
ADMA carries more volatility with a beta of 0.73 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ADMA generates stronger free cash flow (56M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (65/100 vs 49/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?